Your Gleason Score Is Not a Verdict

A man gets a prostate biopsy. A few days later, he receives a number that could change the direction of his life.

Higher Gleason scores often prompt more immediate discussions regarding interventions such as surgery, radiation, or hormone suppression. Many patients interpret the score as a direct indicator of cancer aggressiveness, likelihood of metastasis, and necessary next steps.

However, the Gleason score does not independently provide this comprehensive information.

The Gleason score reflects the microscopic appearance of prostate cells and offers prognostic value. Nonetheless, its limitations are often not thoroughly communicated.

The score is derived from a limited tissue sample and relies on subjective interpretation. It represents a single point in time, does not track disease progression, and cannot independently predict whether treatment will improve survival.

While the Gleason score warrants careful consideration, it should not be regarded as a definitive judgment.

A pathologist examines prostate tissue collected during a biopsy or surgery. The pathologist identifies the two most common cellular patterns and assigns each a grade.

Those two grades are added together.

A Gleason 3 + 3 becomes a 6. A 3 + 4 and a 4 + 3 both add up to 7, but they do not carry the same risk. The first number represents the dominant pattern, so a 4 + 3 contains more pattern 4 tissue than a 3 + 4.

Modern pathology also uses a Grade Group system:

• Grade Group 1: Gleason 3 + 3

• Grade Group 2: Gleason 3 + 4

• Grade Group 3: Gleason 4 + 3

• Grade Group 4: Gleason 8

• Grade Group 5: Gleason 9 or 10

The Grade Group system makes the hierarchy easier to understand. It also prevents men with Gleason 6 from thinking they received a six on a scale beginning at one. Gleason 6 is the lowest contemporary grade assigned to prostate cancer.

Higher-grade patterns are associated with a greater risk of progression, recurrence, and metastasis. The score has value. Problems arise when patients are led to believe that the Gleason score provides all necessary answers about their condition.

A Gleason score does not independently tell you how quickly the cancer is changing. It does not show whether the disease is currently spreading or whether it will remain contained.

It does not tell you how much cancer exists throughout the gland. It cannot confirm that the biopsy needle sampled the highest-grade area. It does not include your PSA history, prostate volume, imaging findings, metabolic health, age, or other medical conditions.

Most of all, it does not tell you whether immediate surgery or radiation will help you live longer.

The Gleason score represents one component of the diagnostic process and should not be considered the sole determinant in clinical decision-making.

Gleason grading is based on visual interpretation. A trained pathologist looks at cellular architecture and decides which patterns are present.

Unlike automated laboratory measurements such as blood glucose levels, Gleason grading requires professional judgment and interpretation.

A nationwide study of 35,258 men in the Netherlands found meaningful variation in Gleason grading between pathology laboratories and among pathologists working within the same laboratory.

A separate blinded study involving 407 prostate biopsy slides found agreement rates of approximately 64% for the primary and secondary Gleason patterns assigned by two pathologists. They also disagreed about whether a tumor was present in some tissue samples.

Another study asked eight pathologists from six institutions to evaluate the same slides. Differences remained, including among specialists.

This variability does not imply that every Gleason score is inaccurate. Rather, it indicates that the score is less absolute than commonly perceived.

When a pathology report is used to support a permanent treatment with potential effects on urinary and sexual function, seeking a second opinion from a genitourinary pathologist is advisable.

For a deeper discussion, listen to my Podcast episode, Why Gleason Scores Fail Men With Prostate Cancer. I explain why one biopsy score should not become the sole basis for an irreversible treatment decision.

The prostate is not uniform.

One area could contain lower-grade cellular patterns while another contains higher-grade tissue. A needle biopsy removes small cores from selected locations. It does not examine every part of the gland.

Even an MRI-targeted biopsy has sampling limitations.

A needle could miss a higher-grade area, producing a score lower than what is found later. Another biopsy or a prostatectomy specimen could then produce a higher grade.

The reverse issue also deserves attention. A small focus of higher-grade tissue in one core could carry enormous influence over a treatment decision, even though the biopsy does not show the full distribution of disease throughout the prostate.

When the score changes after another biopsy or surgery, it does not always mean the cancer suddenly became more aggressive. The difference could come from sampling another part of the gland or from another pathologist interpreting the tissue.

The biopsy result characterizes only the sampled tissue and does not offer a comprehensive assessment of the entire prostate.

The Gleason score is a snapshot. It describes how a selected tissue sample looked on one day. It does not show whether the clinical picture is stable or changing.

That requires sequential assessment.

It is important to assess PSA trends over multiple measurements, prostate size, PSA density, longitudinal imaging findings, symptoms, biomarkers, hormonal and metabolic health, and evidence of disease extension beyond the prostate.

A PSA that rises once and returns to its previous range is different from one that rises steadily across several scheduled tests.

PSA has limitations too. Benign prostate enlargement, inflammation, infection, ejaculation, cycling, instrumentation, medications, and hormonal changes could all influence the result.

No single test provides certainty.

Clinical value is derived from monitoring multiple data points over time and identifying consistent patterns.

Once a man hears the word cancer, the emotional temperature rises. Once he hears a high Gleason score, it rises again.

He begins to feel that every day without treatment gives the cancer more time to spread.

Some prostate cancers require prompt action. Others remain localized or change slowly. The problem is deciding which situation a man is facing without allowing fear to take control.

Alleviating patient anxiety does not necessarily equate to improved clinical outcomes.

Surgery could remove the prostate and lower PSA. It also carries possible effects on urinary continence, erections, ejaculation, and quality of life.

Radiation has its own short-term and long-term consequences. Hormone suppression affects muscle, bone, metabolism, energy, sexual function, and emotional health.

These interventions may be appropriate in specific clinical scenarios. However, patients should be informed about the anticipated benefits and the potential risks to functional outcomes.

A high Gleason score should prompt a comprehensive evaluation rather than serve as the final determinant in decision-making.

The ProtecT trial followed 1,643 men with localized prostate cancer who were assigned to active monitoring, prostatectomy, or radiotherapy. After a median of 15 years, prostate cancer-specific mortality was low across all three groups.

Death from prostate cancer occurred in 3.1% of men assigned to active monitoring, 2.2% assigned to prostatectomy, and 2.9% assigned to radiotherapy. The differences were not statistically significant.

That does not mean the three approaches produced identical outcomes.

Metastases occurred in 9.4% of the active-monitoring group, compared with 4.7% after prostatectomy and 5% after radiotherapy. Clinical progression and the use of long-term hormone suppression were also higher among the men assigned to monitoring.

The monitoring used in ProtecT began more than two decades ago and relied heavily on PSA. It did not include every feature of modern imaging and risk assessment.

These findings demonstrate that many patients with localized prostate cancer have sufficient time to consider their treatment options. The decision-making process should not be oversimplified to an immediate choice between treatment and mortality.

Each option carries a different balance of progression risk, treatment burden, side effects, and quality of life.

A Gleason score usually requires a prostate biopsy. Prostate biopsy is often presented as a routine diagnostic step. It remains an invasive procedure with recognized risks.

These include bleeding, pain, inflammation, difficulty urinating, urinary retention, infection, hospitalization, and sepsis. Transperineal biopsy reduces infection risk compared with the traditional transrectal route, but no invasive procedure is risk-free.

Needle-track seeding has also been documented in published prostate cancer case reports. A 2024 report described a man who developed mucinous prostate cancer recurrence in the rectal wall along the track of a previous transrectal biopsy. The authors described the event as exceedingly rare and cited 42 reported cases of tumor dissemination following prostate needle biopsy.

Although such occurrences are rare, they are not impossible and should be acknowledged in risk discussions.

Before agreeing to any invasive procedure, ask what information it is expected to provide and how that information will change your plan.

If you already have a Gleason score, you do not need to ignore it. You need to place it in context.

1. Ask whether the pathology was reviewed by a genitourinary pathologist.

2. Ask for the Grade Group, not only the combined Gleason total. Find out how much pattern 4 or pattern 5 tissue was present. Ask whether the report identified cribriform architecture or intraductal carcinoma, since these features have separate prognostic significance.

3. Review how many biopsy cores contained cancer and how much cancer appeared in each core.

4. Compare the pathology with the MRI. Look at prostate size, lesion location, possible extension, and changes from earlier imaging.

5. Review the PSA trend instead of reacting to one result.

Then ask the most direct question:

• What outcome is the proposed treatment expected to improve?

Is the goal to lower the risk of metastasis? Improve prostate cancer survival? Relieve symptoms? Reduce anxiety? Each is a different objective.

You also need to ask about the costs. What happens to urinary function, sexual health, bowel function, muscle, energy, and quality of life?

A well-informed decision necessitates consideration of both the potential benefits and risks.

Permanent treatment decisions should not be based solely on a single Gleason score.

A sequential approach that incorporates PSA trends, prostate volume, PSA density, imaging, biomarkers, symptoms, metabolic health, and the overall clinical context is preferable.

If biopsy tissue already exists, an expert second pathology review could provide useful information without repeating the procedure.

Prostate MRI offers information about lesion location, size, gland volume, and possible extension. MRI has limitations and does not provide a microscopic grade, but it creates another point of comparison.

Additional tools such as the Prostate Health Index, 4Kscore, and certain urine or blood tests could add information in selected cases. Each test has a specific purpose, cost, and limitation.

The objective is not to perform every available test, but rather to construct a coherent clinical picture and determine how each result informs the treatment decision.

The Gleason system has helped physicians classify prostate cancer for decades. Higher-grade patterns deserve attention.

But the score is based on selected tissue. It is affected by sampling and interpretation. It does not measure change over time. It cannot determine by itself whether immediate treatment will improve one man’s survival.

It also does not account for what treatment could take away.

A patient’s identity and prognosis extend beyond the findings of a pathology report.

If you have received a Gleason score, slow down long enough to understand it. Confirm the pathology when appropriate. Review the Grade Group and higher-risk tissue patterns. Examine your PSA trend. Compare the findings with imaging.

Ask what each proposed intervention is expected to accomplish.

Permanent decisions should not be made based on incomplete information or emotional responses.

A Gleason score provides useful information about how prostate cancer cells look. It helps estimate risk, but it is not perfectly reproducible and does not provide a complete picture of the prostate or the future.

Pathologists sometimes disagree. A biopsy samples only part of the gland. One result cannot show how the condition is changing.

The score also cannot decide whether surgery, radiation, monitoring, or another approach offers the right balance of benefit and harm for you.

Track changes. Confirm findings. Ask better questions. Understand what you stand to gain and what you risk losing.

Patients typically have sufficient time to become fully informed before making irreversible treatment decisions and are encouraged to utilize this period for thorough consideration.

Stephen Petteruti, DO, is a board-certified family physician with more than 35 years of clinical experience. He is the founder and medical director of Intellectual Medicine, where his work focuses on men’s health, hormone and metabolic health, preventive medicine, and long-term prostate cancer risk assessment.

Dr. Petteruti works directly with men navigating elevated PSA results, prostate imaging, biopsy recommendations, Gleason scores, and prostate cancer treatment decisions. As a family physician rather than a surgeon, he approaches these decisions through a whole-patient lens, examining long-term health, treatment risks, sexual and urinary function, metabolic health, and quality of life.

He is the author of Fight Cancer Like a Man: A Breakthrough Treatment for Prostate Cancer Without Surgery, Radiation, or Sacrificing Your Manhood and host of the Intellectual Medicine Podcast.

1. Flach RN, Willemse PM, Suelmann BBM, et al. Significant inter- and intralaboratory variation in Gleason grading of prostate cancer: a nationwide study of 35,258 patients in the Netherlands. Cancers. 2021;13(21):5375. https://pmc.ncbi.nlm.nih.gov/articles/PMC8582481/

2. Ozkan TA, Eruyar AT, Cebeci OO, et al. Interobserver variability in Gleason histological grading of prostate cancer. Scandinavian Journal of Urology. 2016;50(6):420-424. https://pubmed.ncbi.nlm.nih.gov/27416104/

3. Dere Y, Altun E, Yıldız HT, et al. A grading dilemma: Gleason scoring system. International Journal of Clinical and Experimental Pathology. 2020;13(2):236-249. https://pubmed.ncbi.nlm.nih.gov/32108622/

4. Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. New England Journal of Medicine. 2023;388(17):1547-1558. https://www.nejm.org/doi/full/10.1056/NEJMoa2214122

5. Sosenko A, Owens K, Timoney AG, Hinchliffe A. Non-infectious complications following transrectal prostate needle biopsy. Prostate International. 2022;10(3):157-162. https://pmc.ncbi.nlm.nih.gov/articles/PMC9520411/

6. van Leenders GJLH, van der Kwast TH, Grignon DJ, et al. The 2019 International Society of Urological Pathology consensus conference on grading of prostatic carcinoma. American Journal of Surgical Pathology. 2020;44(8). https://pmc.ncbi.nlm.nih.gov/articles/PMC7382533/

7. Hakariya T, Teshima K, Aoki D, et al. Recurrence of mucinous prostate cancer in rectal wall due to needle-track seeding from previous transrectal prostate biopsy. IJU Case Reports. 2024;7:499-502. https://doi.org/10.1002/iju5.12790